These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 12467491)

  • 21. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease.
    Haan MN
    Nat Clin Pract Neurol; 2006 Mar; 2(3):159-66. PubMed ID: 16932542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linking insulin with Alzheimer's disease: emergence as type III diabetes.
    Ahmed S; Mahmood Z; Zahid S
    Neurol Sci; 2015 Oct; 36(10):1763-9. PubMed ID: 26248483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using thiazolidinediones: rosiglitazone and pioglitazone in clinical practice.
    Peters AL
    Am J Manag Care; 2001 Apr; 7(3 Suppl):S87-95; quiz S96-7. PubMed ID: 11310177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance and Alzheimer's disease: molecular links & clinical implications.
    Neumann KF; Rojo L; Navarrete LP; Farías G; Reyes P; Maccioni RB
    Curr Alzheimer Res; 2008 Oct; 5(5):438-47. PubMed ID: 18855585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones.
    Cardoso S; Moreira PI
    Int Rev Neurobiol; 2020; 155():37-64. PubMed ID: 32854858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].
    Ishmuratova AN; Abramov MA; Kuznetsov KO; Ivanyuta MV; Shakirova ZF; Kitapova AI; Usmonov MD; Chernousova LM; Valeeva LI; Kuznetsova AY; Baislamov AS; Shaihetdinova AR; Mirgaliev AA; Orozberdiev ST; Yakupova KI
    Probl Endokrinol (Mosk); 2023 Nov; 69(5):73-83. PubMed ID: 37968954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Insulin signaling: An opportunistic target to minify the risk of Alzheimer's disease.
    Pardeshi R; Bolshette N; Gadhave K; Ahire A; Ahmed S; Cassano T; Gupta VB; Lahkar M
    Psychoneuroendocrinology; 2017 Sep; 83():159-171. PubMed ID: 28624654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease.
    Blass JP; Gibson GE
    Rev Neurol (Paris); 1991; 147(6-7):513-25. PubMed ID: 1962057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Link between type 2 diabetes and Alzheimer's disease: from epidemiology to mechanism and treatment.
    Li X; Song D; Leng SX
    Clin Interv Aging; 2015; 10():549-60. PubMed ID: 25792818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease.
    Watson GS; Craft S
    Eur J Pharmacol; 2004 Apr; 490(1-3):97-113. PubMed ID: 15094077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosiglitazone.
    Goldstein BJ
    Int J Clin Pract; 2000 Jun; 54(5):333-7. PubMed ID: 10954962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
    Alagiakrishnan K; Sankaralingam S; Ghosh M; Mereu L; Senior P
    Discov Med; 2013 Dec; 16(90):277-86. PubMed ID: 24333407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of insulin resistance in obesity.
    Camejo G; Ljung B; Oakes N
    Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4):275-84. PubMed ID: 11831112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetes drugs in the fight against Alzheimer's disease.
    Boccardi V; Murasecco I; Mecocci P
    Ageing Res Rev; 2019 Sep; 54():100936. PubMed ID: 31330313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus.
    Ohyagi Y; Miyoshi K; Nakamura N
    Adv Exp Med Biol; 2019; 1128():227-248. PubMed ID: 31062332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of thiazolidinediones for early treatment of type 2 diabetes mellitus.
    Kudzma DJ
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S472-82. PubMed ID: 12408410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alzheimer's disease].
    Hanyu H; Sato T
    Nihon Rinsho; 2010 Feb; 68(2):330-4. PubMed ID: 20158105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation.
    Craft S
    Neurobiol Aging; 2005 Dec; 26 Suppl 1():65-9. PubMed ID: 16266773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
    Walter H; Lübben G
    Drugs; 2005; 65(1):1-13. PubMed ID: 15610048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.